Monte Rosa’s MRT-8102 Phase 1 shows deep NEK7 degradation and strong hsCRP drops; plus $200M raise extends runway. Learn more ...

A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease to come back quickly after ...

DelveInsight's Castration-sensitive Prostate Cancer Market Insights report includes a comprehensive understanding of current treatment practices, CSPC emerging drugs, market share of individual ...

The nutritional value of powdered flax seeds stems from their omega-3 fats, fiber content and lignans, which enable people to ...

ASCO GU 2025 had groundbreaking advancements in genitourinary cancer treatments, focusing on prostate cancer, renal cell ...

The results to be presented by Prof Emmett at the EAU Congress 2026 will expand on the earlier findings that the trial met its primary endpoint, demonstrating that 64 Cu-SAR-bisPSMA positron emission ...

Checking PSA levels following treatment is crucial among patients with nonmetastatic, unfavorable risk prostate cancer, according to the co-author of a recent study. Prostate-specific antigen (PSA) ...

Protect your bladder health with these 5 essential health checks. Learn which tests and screenings you need to maintain ...

Here are the top 25 stories of 2025 from Airways, ranked by readership numbers and updated for our year-end wrap-up.

DelveInsight’s “Hepatitis B Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding ...

Medical malpractice: Suit alleges that medical providers failed to properly monitor rising PSA levels, diagnose recurrent prostate cancer, perform timely testing, initiate systemic therapy and make ...

Clarity Pharmaceuticals (ASX: CU6), a clinical-stage radiopharmaceutical company focused on developing next-generation ...